Sugi Predict

Sugi Predict / Compounds / SCHEMBL2654350

SCHEMBL2654350

SCHEMBL2654350

Cc1cc(C)c(I)c(O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SELL P14151 1/20 0.50
▸ SELP P16109 1/20 0.50
▸ SELE P16581 1/20 0.50
▸ ACHE P22303 1/20 0.50
▸ TP53 P04637 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ ACLY P53396 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ GAA P10253 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ TRPA1 O75762 2/20 0.40
▸ POLB P06746 1/20 0.37
▸ APEX1 P27695 1/20 0.37
▸ MPI P34949 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ RAPGEF4 Q8WZA2 4/20 0.36
▸ CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31090197 1.00 SELL (0.50) SELLSELPSELEACHETP53
SCHEMBL16621851 0.86 SELL (0.58) SELLSELPSELEACHETP53
SCHEMBL760815 0.80 RAPGEF4 (0.45) SELLSELPSELEACHETP53
SCHEMBL1109760 0.77 RAPGEF4 (0.43) SELLSELPSELEACHETP53
Hydrochloric Acid SCHEMBL29360453 0.77 RAPGEF4 (0.43) SELLSELPSELEACHETP53
Hydrochloric Acid SCHEMBL30511867 0.77 RAPGEF4 (0.43) SELLSELPSELEACHETP53
SCHEMBL9359704 0.77 RAPGEF4 (0.43) SELLSELPSELEACHETP53
SCHEMBL25085872 0.75 ALDH1A1 (0.41) TDP1ACLYALDH1A1KDM4EMAPT
SCHEMBL31200564 0.75 SELL (0.46) SELLSELPSELEACHEACLY
SCHEMBL30994085 0.75 PTGS1 (0.38) TP53TDP1ACLYALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4613749-A1 NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF TransThera Sciences (Nanjing), Inc. (CN) 2025-09-10 — — EP disclosed
US-20250270188-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS AG (CH) 2025-08-28 — — US disclosed
EP-4568975-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2025-06-18 — — EP disclosed
CN-119732956-A NLRP3 inflammatory corpuscle inhibitor 诺华股份有限公司 2025-04-01 — — CN disclosed
CN-113784957-B NLRP3 inflammatory corpuscle inhibitor 诺华股份有限公司 2025-02-28 — — CN disclosed
US-20250002470-A1 NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ZHEJIANG AIXPLORER BIOTECH CO., LTD. (CN) 2025-01-02 — — US disclosed
US-12139471-B2 NLRP3 inflammasome inhibitors NOVARTIS AG (CH) 2024-11-12 — — US disclosed
CN-118852153-A NLRP3 inflammation corpuscle inhibitor and application thereof 药捷安康(南京)科技股份有限公司 2024-10-29 — — CN disclosed
EP-4419532-A1 FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2024-08-28 — — EP disclosed
EP-4421068-A1 NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Zhejiang Aixplorer Biotech Co., Ltd. (CN) 2024-08-28 — — EP disclosed
US-11208399-B2 NLRP3 inflammasome inhibitors NOVARTIS AG (CH) 2021-12-28 — — US disclosed
US-11208399-B2 NLRP3 inflammasome inhibitors NOVARTIS AG (CH) 2021-12-28 — — US disclosed
CN-113784957-A NLRP3 inflammasome inhibitor 诺华股份有限公司 2021-12-10 — — CN disclosed
WO-2020234715-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS AG (CH) 2020-11-26 — — WO disclosed
US-20200361898-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS PHARMA AG (CH) 2020-11-19 — — US disclosed
US-20200361898-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS PHARMA AG (CH) 2020-11-19 — — US disclosed
US-20200361899-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS PHARMA AG (CH) 2020-11-19 — — US disclosed
US-20200361899-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS PHARMA AG (CH) 2020-11-19 — — US disclosed
EP-1856090-A2 SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-11-21 — — EP disclosed
WO-2006086488-A2 SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361898-A1 NLRP3 INFLAMMASOME INHIBITORS NLRP3, NLRP1, NOD1 SELL 2882/4885SELP 2115/4885SELE 3964/4885
US-20250002470-A1 NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF NOD1, NLRP3, NLRP1 SELL 1366/4885SELP 2491/4885SELE 4141/4885
US-20200361899-A1 NLRP3 INFLAMMASOME INHIBITORS NLRP3, NLRP1, NOD1 SELL 2882/4885SELP 2115/4885SELE 3964/4885
US-12139471-B2 NLRP3 inflammasome inhibitors NLRP3, NLRP1, NOD1 SELL 2882/4885SELP 2115/4885SELE 3964/4885
US-11208399-B2 NLRP3 inflammasome inhibitors NLRP3, NLRP1, NOD1 SELL 2882/4885SELP 2115/4885SELE 3964/4885
US-20250270188-A1 NLRP3 INFLAMMASOME INHIBITORS NLRP3, NLRP1, NOD1 SELL 2882/4885SELP 2115/4885SELE 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.